245 related articles for article (PubMed ID: 30278072)
1. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
[TBL] [Abstract][Full Text] [Related]
2. DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.
Wang D; Qian X; Rajaram M; Durkin ME; Lowy DR
Oncotarget; 2016 Jul; 7(29):45144-45157. PubMed ID: 27174913
[TBL] [Abstract][Full Text] [Related]
3. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter.
Liu Y; Zhou J; Hu Y; Wang J; Yuan C
Mol Cell Biochem; 2017 Jan; 425(1-2):47-58. PubMed ID: 27830358
[TBL] [Abstract][Full Text] [Related]
5. [Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Feng Y; Zhou HX; Li JH; Li ZY; Cheng WG; Jin ML; He L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1448-51. PubMed ID: 21868344
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer.
Dai Z; Jin Y
Oncol Rep; 2013 Sep; 30(3):1511-7. PubMed ID: 23783552
[TBL] [Abstract][Full Text] [Related]
7. Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.
Singh D; Bharti A; Biswas D; Tewari M; Kar AG; Ansari MA; Singh S; Narayan G
J Gastrointest Cancer; 2022 Jun; 53(2):237-244. PubMed ID: 33417200
[TBL] [Abstract][Full Text] [Related]
8. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
9. Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.
Hankins GR; Sasaki T; Lieu AS; Saulle D; Karimi K; Li JZ; Helm GA
Neurosurgery; 2008 Oct; 63(4):771-80; discussion 780-1. PubMed ID: 18981889
[TBL] [Abstract][Full Text] [Related]
10. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
[TBL] [Abstract][Full Text] [Related]
11. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
12. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
13. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
14. Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.
Bujko M; Kober P; Rusetska N; Wakuła M; Goryca K; Grecka E; Matyja E; Neska J; Mandat T; Bonicki W; Siedlecki JA
J Neurooncol; 2016 Dec; 130(3):473-484. PubMed ID: 27614886
[TBL] [Abstract][Full Text] [Related]
15. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
Nasif D; Campoy E; Laurito S; Branham R; Urrutia G; Roqué M; Branham MT
Clin Epigenetics; 2018 Aug; 10(1):111. PubMed ID: 30139383
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines.
Ullmannova V; Popescu NC
Cancer Detect Prev; 2007; 31(2):110-8. PubMed ID: 17418982
[TBL] [Abstract][Full Text] [Related]
18. Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome.
Dai X; Li L; Liu X; Hu W; Yang Y; Bai Z
G3 (Bethesda); 2014 Nov; 5(1):81-91. PubMed ID: 25425654
[TBL] [Abstract][Full Text] [Related]
19. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis.
Qin Y; Chu B; Gong W; Wang J; Tang Z; Shen J; Quan Z
J Gastroenterol Hepatol; 2014 May; 29(5):964-72. PubMed ID: 24329682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
